nodes	percent_of_prediction	percent_of_DWPC	metapath
Almotriptan—Parosmia—Varenicline—nicotine dependence	0.0215	0.0349	CcSEcCtD
Almotriptan—Nystagmus—Varenicline—nicotine dependence	0.0195	0.0317	CcSEcCtD
Almotriptan—Scotoma—Varenicline—nicotine dependence	0.0183	0.0298	CcSEcCtD
Almotriptan—CYP2E1—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0172	0.0458	CbGpPWpGaD
Almotriptan—Eye irritation—Varenicline—nicotine dependence	0.0163	0.0265	CcSEcCtD
Almotriptan—Disturbance in attention—Varenicline—nicotine dependence	0.0161	0.0261	CcSEcCtD
Almotriptan—Gastrooesophageal reflux disease—Varenicline—nicotine dependence	0.0154	0.025	CcSEcCtD
Almotriptan—CYP2C8—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0149	0.0396	CbGpPWpGaD
Almotriptan—Coordination abnormal—Varenicline—nicotine dependence	0.0142	0.023	CcSEcCtD
Almotriptan—Salivary hypersecretion—Varenicline—nicotine dependence	0.0135	0.022	CcSEcCtD
Almotriptan—Nightmare—Varenicline—nicotine dependence	0.0134	0.0218	CcSEcCtD
Almotriptan—CYP2C19—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0133	0.0353	CbGpPWpGaD
Almotriptan—Dry eye—Varenicline—nicotine dependence	0.0129	0.0209	CcSEcCtD
Almotriptan—FMO3—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0122	0.0326	CbGpPWpGaD
Almotriptan—Hypertonia—Varenicline—nicotine dependence	0.0122	0.0198	CcSEcCtD
Almotriptan—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0122	0.0325	CbGpPWpGaD
Almotriptan—Mental disability—Varenicline—nicotine dependence	0.0121	0.0196	CcSEcCtD
Almotriptan—Euphoric mood—Varenicline—nicotine dependence	0.012	0.0194	CcSEcCtD
Almotriptan—Eye pain—Varenicline—nicotine dependence	0.0112	0.0182	CcSEcCtD
Almotriptan—CYP2E1—Xenobiotics—CYP2A7—nicotine dependence	0.0107	0.0284	CbGpPWpGaD
Almotriptan—Thirst—Varenicline—nicotine dependence	0.0106	0.0173	CcSEcCtD
Almotriptan—Arthritis—Varenicline—nicotine dependence	0.0104	0.0169	CcSEcCtD
Almotriptan—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.00952	0.0254	CbGpPWpGaD
Almotriptan—Abdominal pain upper—Varenicline—nicotine dependence	0.00923	0.015	CcSEcCtD
Almotriptan—CYP2C8—Xenobiotics—CYP2A7—nicotine dependence	0.00921	0.0245	CbGpPWpGaD
Almotriptan—Breast disorder—Varenicline—nicotine dependence	0.00913	0.0148	CcSEcCtD
Almotriptan—Gastritis—Varenicline—nicotine dependence	0.00894	0.0145	CcSEcCtD
Almotriptan—Sumatriptan—DRD2—nicotine dependence	0.00894	1	CrCbGaD
Almotriptan—Angina pectoris—Varenicline—nicotine dependence	0.00851	0.0138	CcSEcCtD
Almotriptan—Bronchitis—Varenicline—nicotine dependence	0.0084	0.0136	CcSEcCtD
Almotriptan—Abdominal discomfort—Varenicline—nicotine dependence	0.00837	0.0136	CcSEcCtD
Almotriptan—CYP2C19—Xenobiotics—CYP2A7—nicotine dependence	0.00822	0.0219	CbGpPWpGaD
Almotriptan—Photosensitivity reaction—Varenicline—nicotine dependence	0.00797	0.013	CcSEcCtD
Almotriptan—Hyperglycaemia—Varenicline—nicotine dependence	0.00788	0.0128	CcSEcCtD
Almotriptan—Acute coronary syndrome—Varenicline—nicotine dependence	0.00768	0.0125	CcSEcCtD
Almotriptan—Myocardial infarction—Varenicline—nicotine dependence	0.00763	0.0124	CcSEcCtD
Almotriptan—Conjunctivitis—Varenicline—nicotine dependence	0.00757	0.0123	CcSEcCtD
Almotriptan—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00756	0.0201	CbGpPWpGaD
Almotriptan—Epistaxis—Varenicline—nicotine dependence	0.00735	0.0119	CcSEcCtD
Almotriptan—Sinusitis—Varenicline—nicotine dependence	0.00731	0.0119	CcSEcCtD
Almotriptan—Hypoaesthesia—Varenicline—nicotine dependence	0.00696	0.0113	CcSEcCtD
Almotriptan—FMO3—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00689	0.0184	CbGpPWpGaD
Almotriptan—Visual impairment—Varenicline—nicotine dependence	0.00674	0.0109	CcSEcCtD
Almotriptan—FMO3—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00674	0.0179	CbGpPWpGaD
Almotriptan—Eye disorder—Varenicline—nicotine dependence	0.00653	0.0106	CcSEcCtD
Almotriptan—Tinnitus—Varenicline—nicotine dependence	0.00652	0.0106	CcSEcCtD
Almotriptan—FMO3—Biological oxidations—CYP2A7—nicotine dependence	0.0065	0.0173	CbGpPWpGaD
Almotriptan—Cardiac disorder—Varenicline—nicotine dependence	0.00649	0.0105	CcSEcCtD
Almotriptan—FMO3—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00641	0.0171	CbGpPWpGaD
Almotriptan—CYP1A2—Xenobiotics—CYP2A7—nicotine dependence	0.00641	0.0171	CbGpPWpGaD
Almotriptan—Immune system disorder—Varenicline—nicotine dependence	0.00631	0.0103	CcSEcCtD
Almotriptan—Chills—Varenicline—nicotine dependence	0.00627	0.0102	CcSEcCtD
Almotriptan—HTR1D—Monoamine GPCRs—DRD2—nicotine dependence	0.00627	0.0167	CbGpPWpGaD
Almotriptan—HTR1B—Monoamine GPCRs—DRD2—nicotine dependence	0.00614	0.0164	CbGpPWpGaD
Almotriptan—Mental disorder—Varenicline—nicotine dependence	0.00612	0.00995	CcSEcCtD
Almotriptan—Erythema—Varenicline—nicotine dependence	0.00609	0.00989	CcSEcCtD
Almotriptan—Dysgeusia—Varenicline—nicotine dependence	0.00596	0.00968	CcSEcCtD
Almotriptan—Back pain—Varenicline—nicotine dependence	0.00589	0.00956	CcSEcCtD
Almotriptan—MAOA—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00585	0.0156	CbGpPWpGaD
Almotriptan—Vision blurred—Varenicline—nicotine dependence	0.00574	0.00932	CcSEcCtD
Almotriptan—Tremor—Varenicline—nicotine dependence	0.0057	0.00926	CcSEcCtD
Almotriptan—Ill-defined disorder—Varenicline—nicotine dependence	0.00565	0.00917	CcSEcCtD
Almotriptan—Agitation—Varenicline—nicotine dependence	0.00559	0.00909	CcSEcCtD
Almotriptan—Angioedema—Varenicline—nicotine dependence	0.00556	0.00904	CcSEcCtD
Almotriptan—Malaise—Varenicline—nicotine dependence	0.00549	0.00892	CcSEcCtD
Almotriptan—Vertigo—Varenicline—nicotine dependence	0.00547	0.00888	CcSEcCtD
Almotriptan—Syncope—Varenicline—nicotine dependence	0.00546	0.00887	CcSEcCtD
Almotriptan—Palpitations—Varenicline—nicotine dependence	0.00538	0.00874	CcSEcCtD
Almotriptan—Loss of consciousness—Varenicline—nicotine dependence	0.00535	0.00869	CcSEcCtD
Almotriptan—Convulsion—Varenicline—nicotine dependence	0.00527	0.00857	CcSEcCtD
Almotriptan—HTR1D—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00527	0.014	CbGpPWpGaD
Almotriptan—Hypertension—Varenicline—nicotine dependence	0.00525	0.00854	CcSEcCtD
Almotriptan—Arthralgia—Varenicline—nicotine dependence	0.00518	0.00842	CcSEcCtD
Almotriptan—Chest pain—Varenicline—nicotine dependence	0.00518	0.00842	CcSEcCtD
Almotriptan—Myalgia—Varenicline—nicotine dependence	0.00518	0.00842	CcSEcCtD
Almotriptan—Anxiety—Varenicline—nicotine dependence	0.00516	0.00839	CcSEcCtD
Almotriptan—HTR1B—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00516	0.0138	CbGpPWpGaD
Almotriptan—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00515	0.00836	CcSEcCtD
Almotriptan—Discomfort—Varenicline—nicotine dependence	0.00512	0.00832	CcSEcCtD
Almotriptan—Dry mouth—Varenicline—nicotine dependence	0.00507	0.00823	CcSEcCtD
Almotriptan—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00494	0.0132	CbGpPWpGaD
Almotriptan—Shock—Varenicline—nicotine dependence	0.00489	0.00794	CcSEcCtD
Almotriptan—Nervous system disorder—Varenicline—nicotine dependence	0.00487	0.00791	CcSEcCtD
Almotriptan—Tachycardia—Varenicline—nicotine dependence	0.00485	0.00788	CcSEcCtD
Almotriptan—Skin disorder—Varenicline—nicotine dependence	0.00482	0.00784	CcSEcCtD
Almotriptan—Hyperhidrosis—Varenicline—nicotine dependence	0.0048	0.0078	CcSEcCtD
Almotriptan—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00453	0.00735	CcSEcCtD
Almotriptan—FMO3—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00449	0.012	CbGpPWpGaD
Almotriptan—Insomnia—Varenicline—nicotine dependence	0.00449	0.0073	CcSEcCtD
Almotriptan—Dyspnoea—Varenicline—nicotine dependence	0.00443	0.00719	CcSEcCtD
Almotriptan—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00442	0.0118	CbGpPWpGaD
Almotriptan—Somnolence—Varenicline—nicotine dependence	0.00442	0.00717	CcSEcCtD
Almotriptan—Dyspepsia—Varenicline—nicotine dependence	0.00437	0.0071	CcSEcCtD
Almotriptan—CYP2E1—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00437	0.0116	CbGpPWpGaD
Almotriptan—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00429	0.00697	CcSEcCtD
Almotriptan—Fatigue—Varenicline—nicotine dependence	0.00428	0.00696	CcSEcCtD
Almotriptan—HTR1D—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00428	0.0114	CbGpPWpGaD
Almotriptan—Pain—Varenicline—nicotine dependence	0.00425	0.0069	CcSEcCtD
Almotriptan—HTR1B—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00419	0.0112	CbGpPWpGaD
Almotriptan—Feeling abnormal—Varenicline—nicotine dependence	0.00409	0.00665	CcSEcCtD
Almotriptan—FMO3—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00408	0.0109	CbGpPWpGaD
Almotriptan—Gastrointestinal pain—Varenicline—nicotine dependence	0.00406	0.0066	CcSEcCtD
Almotriptan—MAOA—Transmission across Chemical Synapses—CHRNB3—nicotine dependence	0.00402	0.0107	CbGpPWpGaD
Almotriptan—Body temperature increased—Varenicline—nicotine dependence	0.00393	0.00638	CcSEcCtD
Almotriptan—Abdominal pain—Varenicline—nicotine dependence	0.00393	0.00638	CcSEcCtD
Almotriptan—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00382	0.0102	CbGpPWpGaD
Almotriptan—MAOA—Transmission across Chemical Synapses—CHRNA6—nicotine dependence	0.00381	0.0101	CbGpPWpGaD
Almotriptan—CYP2C8—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00377	0.0101	CbGpPWpGaD
Almotriptan—Hypersensitivity—Varenicline—nicotine dependence	0.00366	0.00595	CcSEcCtD
Almotriptan—CYP2E1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00359	0.00956	CbGpPWpGaD
Almotriptan—Asthenia—Varenicline—nicotine dependence	0.00356	0.00579	CcSEcCtD
Almotriptan—Pruritus—Varenicline—nicotine dependence	0.00351	0.00571	CcSEcCtD
Almotriptan—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00341	0.0091	CbGpPWpGaD
Almotriptan—Diarrhoea—Varenicline—nicotine dependence	0.0034	0.00552	CcSEcCtD
Almotriptan—CYP2C19—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00337	0.00898	CbGpPWpGaD
Almotriptan—Dizziness—Varenicline—nicotine dependence	0.00328	0.00534	CcSEcCtD
Almotriptan—MAOA—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00322	0.00858	CbGpPWpGaD
Almotriptan—Vomiting—Varenicline—nicotine dependence	0.00316	0.00513	CcSEcCtD
Almotriptan—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00314	0.00837	CbGpPWpGaD
Almotriptan—Rash—Varenicline—nicotine dependence	0.00313	0.00509	CcSEcCtD
Almotriptan—Dermatitis—Varenicline—nicotine dependence	0.00313	0.00508	CcSEcCtD
Almotriptan—Headache—Varenicline—nicotine dependence	0.00311	0.00506	CcSEcCtD
Almotriptan—MAOA—Biological oxidations—CYP2A7—nicotine dependence	0.00311	0.00827	CbGpPWpGaD
Almotriptan—CYP2C8—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0031	0.00826	CbGpPWpGaD
Almotriptan—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.0031	0.00826	CbGpPWpGaD
Almotriptan—MAOA—Neuronal System—CHRNB3—nicotine dependence	0.00308	0.0082	CbGpPWpGaD
Almotriptan—Nausea—Varenicline—nicotine dependence	0.00295	0.00479	CcSEcCtD
Almotriptan—MAOA—Neuronal System—CHRNA6—nicotine dependence	0.00292	0.00777	CbGpPWpGaD
Almotriptan—CYP2C19—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00277	0.00737	CbGpPWpGaD
Almotriptan—MAOA—Transmission across Chemical Synapses—GABRA4—nicotine dependence	0.00275	0.00733	CbGpPWpGaD
Almotriptan—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00266	0.00709	CbGpPWpGaD
Almotriptan—MAOA—Transmission across Chemical Synapses—CHRNB4—nicotine dependence	0.00264	0.00703	CbGpPWpGaD
Almotriptan—CYP1A2—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00262	0.00699	CbGpPWpGaD
Almotriptan—HTR1D—GPCR ligand binding—TAS2R16—nicotine dependence	0.00259	0.0069	CbGpPWpGaD
Almotriptan—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00255	0.00678	CbGpPWpGaD
Almotriptan—HTR1B—GPCR ligand binding—TAS2R16—nicotine dependence	0.00254	0.00676	CbGpPWpGaD
Almotriptan—MAOA—Transmission across Chemical Synapses—CHRNA5—nicotine dependence	0.00245	0.00654	CbGpPWpGaD
Almotriptan—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00216	0.00575	CbGpPWpGaD
Almotriptan—MAOA—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00215	0.00572	CbGpPWpGaD
Almotriptan—MAOA—Neuronal System—GABRA4—nicotine dependence	0.00211	0.00562	CbGpPWpGaD
Almotriptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00205	0.00547	CbGpPWpGaD
Almotriptan—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00203	0.0054	CbGpPWpGaD
Almotriptan—MAOA—Neuronal System—CHRNB4—nicotine dependence	0.00202	0.00539	CbGpPWpGaD
Almotriptan—CYP2E1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00202	0.00539	CbGpPWpGaD
Almotriptan—MAOA—Transmission across Chemical Synapses—CHRNA3—nicotine dependence	0.002	0.00533	CbGpPWpGaD
Almotriptan—MAOA—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00195	0.0052	CbGpPWpGaD
Almotriptan—CYP2E1—Biological oxidations—CYP2A7—nicotine dependence	0.00191	0.00508	CbGpPWpGaD
Almotriptan—MAOA—Neuronal System—CHRNA5—nicotine dependence	0.00188	0.00501	CbGpPWpGaD
Almotriptan—CYP2E1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00188	0.00501	CbGpPWpGaD
Almotriptan—HTR1D—G alpha (i) signalling events—OPRM1—nicotine dependence	0.0018	0.00481	CbGpPWpGaD
Almotriptan—HTR1B—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00177	0.00471	CbGpPWpGaD
Almotriptan—MAOA—Transmission across Chemical Synapses—CHRNB2—nicotine dependence	0.00176	0.00469	CbGpPWpGaD
Almotriptan—CYP2C8—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00175	0.00466	CbGpPWpGaD
Almotriptan—HTR1D—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00167	0.00446	CbGpPWpGaD
Almotriptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00166	0.00443	CbGpPWpGaD
Almotriptan—CYP2C8—Biological oxidations—CYP2A7—nicotine dependence	0.00165	0.00439	CbGpPWpGaD
Almotriptan—HTR1B—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00164	0.00437	CbGpPWpGaD
Almotriptan—CYP2C8—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00162	0.00433	CbGpPWpGaD
Almotriptan—MAOA—Transmission across Chemical Synapses—CHRNA4—nicotine dependence	0.0016	0.00426	CbGpPWpGaD
Almotriptan—CYP2C19—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00156	0.00416	CbGpPWpGaD
Almotriptan—MAOA—Neuronal System—CHRNA3—nicotine dependence	0.00153	0.00408	CbGpPWpGaD
Almotriptan—CYP2C19—Biological oxidations—CYP2A7—nicotine dependence	0.00147	0.00392	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00146	0.0039	CbGpPWpGaD
Almotriptan—CYP2C19—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00145	0.00386	CbGpPWpGaD
Almotriptan—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00143	0.00382	CbGpPWpGaD
Almotriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00143	0.00382	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00143	0.00382	CbGpPWpGaD
Almotriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.0014	0.00374	CbGpPWpGaD
Almotriptan—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.00135	0.0036	CbGpPWpGaD
Almotriptan—MAOA—Neuronal System—CHRNB2—nicotine dependence	0.00135	0.00359	CbGpPWpGaD
Almotriptan—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00133	0.00355	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—TAS2R16—nicotine dependence	0.00133	0.00354	CbGpPWpGaD
Almotriptan—HTR1D—G alpha (i) signalling events—DRD2—nicotine dependence	0.0013	0.00347	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—TAS2R16—nicotine dependence	0.0013	0.00347	CbGpPWpGaD
Almotriptan—HTR1B—G alpha (i) signalling events—DRD2—nicotine dependence	0.00128	0.0034	CbGpPWpGaD
Almotriptan—MAOA—Neuronal System—CHRNA4—nicotine dependence	0.00123	0.00326	CbGpPWpGaD
Almotriptan—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00122	0.00324	CbGpPWpGaD
Almotriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00121	0.00322	CbGpPWpGaD
Almotriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00118	0.00316	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—FGD1—nicotine dependence	0.00115	0.00306	CbGpPWpGaD
Almotriptan—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	0.00115	0.00305	CbGpPWpGaD
Almotriptan—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00113	0.00301	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—FGD1—nicotine dependence	0.00112	0.003	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—CYP2A7—nicotine dependence	0.00111	0.00296	CbGpPWpGaD
Almotriptan—HTR1D—GPCR ligand binding—OPRM1—nicotine dependence	0.00109	0.00291	CbGpPWpGaD
Almotriptan—HTR1B—GPCR ligand binding—OPRM1—nicotine dependence	0.00107	0.00285	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—FGD1—nicotine dependence	0.00104	0.00278	CbGpPWpGaD
Almotriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00104	0.00276	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—FGD1—nicotine dependence	0.00102	0.00272	CbGpPWpGaD
Almotriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00102	0.00271	CbGpPWpGaD
Almotriptan—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000938	0.0025	CbGpPWpGaD
Almotriptan—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000884	0.00236	CbGpPWpGaD
Almotriptan—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000872	0.00232	CbGpPWpGaD
Almotriptan—HTR1D—GPCR ligand binding—DRD2—nicotine dependence	0.00079	0.0021	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—TAS2R16—nicotine dependence	0.000785	0.00209	CbGpPWpGaD
Almotriptan—HTR1B—GPCR ligand binding—DRD2—nicotine dependence	0.000773	0.00206	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—TAS2R16—nicotine dependence	0.000769	0.00205	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—OPRM1—nicotine dependence	0.000617	0.00164	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—FGD1—nicotine dependence	0.000616	0.00164	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—OPRM1—nicotine dependence	0.000604	0.00161	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—FGD1—nicotine dependence	0.000603	0.00161	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—OPRM1—nicotine dependence	0.00056	0.00149	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—OPRM1—nicotine dependence	0.000549	0.00146	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—AKR1B10—nicotine dependence	0.000544	0.00145	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—AKR1B10—nicotine dependence	0.000533	0.00142	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—CYP2A7—nicotine dependence	0.000531	0.00142	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—DRD2—nicotine dependence	0.000446	0.00119	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—DRD2—nicotine dependence	0.000437	0.00116	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—DRD2—nicotine dependence	0.000405	0.00108	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—DRD2—nicotine dependence	0.000397	0.00106	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—WASF2—nicotine dependence	0.000384	0.00102	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—WASF2—nicotine dependence	0.000376	0.001	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—WASF1—nicotine dependence	0.000368	0.00098	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—WASF1—nicotine dependence	0.00036	0.000959	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—OPRM1—nicotine dependence	0.000331	0.000882	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—CYP2A7—nicotine dependence	0.000326	0.000868	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—OPRM1—nicotine dependence	0.000324	0.000864	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—CYP2A7—nicotine dependence	0.000282	0.00075	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—CYP2A7—nicotine dependence	0.000251	0.00067	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—DRD2—nicotine dependence	0.000239	0.000638	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—DRD2—nicotine dependence	0.000234	0.000625	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—CYP2A7—nicotine dependence	0.000231	0.000616	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—CYP2A7—nicotine dependence	0.000196	0.000522	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—CYP2A7—nicotine dependence	0.000151	0.000403	CbGpPWpGaD
Almotriptan—HTR1B—cardiovascular system—nicotine dependence	3.46e-05	0.12	CbGeAlD
Almotriptan—HTR1D—cardiovascular system—nicotine dependence	3.35e-05	0.116	CbGeAlD
Almotriptan—FMO3—brain—nicotine dependence	2.89e-05	0.1	CbGeAlD
Almotriptan—HTR1B—midbrain—nicotine dependence	2.7e-05	0.0936	CbGeAlD
Almotriptan—HTR1D—midbrain—nicotine dependence	2.62e-05	0.0906	CbGeAlD
Almotriptan—MAOA—cardiovascular system—nicotine dependence	2.55e-05	0.0883	CbGeAlD
Almotriptan—MAOA—midbrain—nicotine dependence	1.99e-05	0.069	CbGeAlD
Almotriptan—CYP2E1—cardiovascular system—nicotine dependence	1.91e-05	0.0663	CbGeAlD
Almotriptan—HTR1B—brain—nicotine dependence	1.7e-05	0.0588	CbGeAlD
Almotriptan—HTR1D—brain—nicotine dependence	1.64e-05	0.0569	CbGeAlD
Almotriptan—MAOA—brain—nicotine dependence	1.25e-05	0.0433	CbGeAlD
Almotriptan—CYP2C8—brain—nicotine dependence	1.12e-05	0.0386	CbGeAlD
Almotriptan—CYP2E1—brain—nicotine dependence	9.4e-06	0.0325	CbGeAlD
Almotriptan—CYP2D6—brain—nicotine dependence	7.44e-06	0.0258	CbGeAlD
